s0122230
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.400
- ESTROGEN_RESPONSE_LATE+0.400
- BILE_ACID_METABOLISM+0.300
- CHOLESTEROL_HOMEOSTASIS+0.300
- KRAS_SIGNALING_DN+0.300
- NOTCH_SIGNALING+0.300
- P53_PATHWAY+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- APICAL_SURFACE+0.200
- PEROXISOME+0.200
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V1-0.500
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- ANGIOGENESIS-0.300
- DNA_REPAIR-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
- MITOTIC_SPINDLE-0.300
- PANCREAS_BETA_CELLS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0112300 | — | — | 0.891 |
| 2 | s0112302 | — | — | 0.882 |
| 3 | ERR2208930 | — | — | 0.846 |
| 4 | s0112264 | — | — | 0.831 |
| 5 | c52d39b7-3811-41e5-bdc8-9ed59632a903 | — | — | 0.825 |
| 6 | SRR1313116 | — | A | 0.796 |
| 7 | s0112281 | — | — | 0.794 |
| 8 | 433318f9-74f1-4d4a-b94c-5825993747d4 | — | — | 0.782 |
| 9 | MNG795 | — | — | 0.782 |
| 10 | BS_MKP2Y41Z | Posterior Fossa Ependymoma | — | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |